New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The report said the FDA worked too closely with Biogen despite significant concerns over the limited benefits and side effects of the new drug, Aduhelm. Geoff Bennett reports.
Stream your PBS favorites with the PBS app: https://to.pbs.org/2Jb8twG
Find more from PBS NewsHour at https://www.pbs.org/newshour
Subscribe to our YouTube channel: https://bit.ly/2HfsCD6
Follow us:
TikTok: https://www.tiktok.com/@pbsnews
Twitter: https://www.twitter.com/newshour
Instagram: https://www.instagram.com/newshour
Facebook: https://www.pbs.org/newshour
Subscribe:
PBS NewsHour podcasts: https://www.pbs.org/newshour/podcasts
Newsletters: https://www.pbs.org/newshour/subscribe
